HOUSE DEVICE REFORM "SCOPE OF REVIEW" COMPROMISE HAS SUPPORT OF SEN. KENNEDY, INDUSTRY; SENATE PASSES FDA REFORM BILL BY 98-2 ON SEPT. 24
This article was originally published in The Gray Sheet
Executive Summary
A compromise reached by FDA and the House Commerce Committee on scope of review language in the House FDA device reform bill (HR 1710) has the support of Sen. Edward Kennedy (D-Mass.) and device manufacturers, bolstering the prospects for adoption of the language during conference on the legislation.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.